

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	PAT051386-US-CIP01
First Inventor	BARNETT et al.
Title	POLYNUCLEOTIDES ENCODING ANTIGEN
Express Mail Label No.	N/A

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☐ **Fee Transmittal Form** (e.g., PTO/SB/17)
2. ☐ **Applicant claims small entity status.**
See 37 CFR 1.27.
3. ☐ **Specification** [Total Pages _____]
Both the claims and abstract must start on a new page
(For information on the preferred arrangement, see MPEP 608.01(a))
4. ☐ **Drawing(s)** (35 U.S.C. 113) [Total Sheets _____]
5. **Oath or Declaration** [Total Sheets _____]
a. ☐ Newly executed (original or copy)
b. ☐ A copy from a prior application (37 CFR 1.33(d))
(for continuation/divisional with Box 18 completed)
i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attaches deleting inventor(s)
name in the prior application, see 37 CFR
1.62(d)(2) and 1.33(b).
6. ☐ **Application Data Sheet.** See 37 CFR 1.76
7. ☐ **CD-ROM or CD-R** in duplicate, large table or
Computer Program (Appendix)
☐ Landscape Table on CD
8. **Nucleotide and/or Amino Acid Sequence Submission**
(if applicable, items a. - c. are required)
a. ☐ Computer Readable Form (CRF)
b. ☐ Specification Sequence Listing on:
i. ☐ CD-ROM or CD-R (2 copies); or
ii. ☐ Paper
c. ☐ Statements verifying identity of above copies

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. _____

Prior application information: Examiner _____ Air Unit _____

19. CORRESPONDENCE ADDRESS

☒ The address associated with Customer Number: 27476 OR ☐ Correspondence address below

Name

Address

City

Country

State

Telephone

Zip Code

Email

Signature

Date

Name
(Print/Type)

Regina Baušta

December 31, 2010

Registration No.
(Attorney/Agent)

46,280

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR §1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office on

Date: December 31, 2010

Signature: /Christy Snyder/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : BARNETT, et al.

Art Unit : 1635

Serial No. : 09/610,313

Examiner : Angell, Jon E.

Filed : July 5, 2000

Conf. No. : 4221

Title : PLOYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C
POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

RESPONSE TO THE NOTICE DENIAL OF
REQUEST FOR POWER OF ATTORNEY

This is a reply to the Notice of Denial of Request for Power of Attorney, dated December 9, 2010. No fees are believed to be due.

It is respectfully requested that the Office of Data Management grant the request for Power of Attorney and accept this resubmitted Power of Attorney along with a 3.73(b) form including attachments.

Docket: : PAT051386-US-CIP01
Applicant : BARNETT, et al.
Serial No. : 09/610,313
Filed : July 5, 2000
Page : 2 of 2

PATENT


Should there be any outstanding matters that need to be resolved in the present application; the Examiner is respectfully requested to contact Regina Bautista (Reg. No. 46,280) at the telephone number of the undersigned below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 03-1664 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

Novartis Vaccines & Diagnostics, Inc.

December 31, 2010

By: 
Regina Bautista
Registration No. 46,280

Novartis Vaccines & Diagnostics, Inc.
IP Services Bldg X-100B
Emeryville, CA 94609-2916
Phone: (617) 871-8088